Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
“All-causes discontinuation” refers to discontinuation of treatment for any reason, and medication adherence is an important component of this measure. Similar to our previous results, we found that almost 30% of patients with first-episode psychosis (FEP) discontinue medication in the first 9 months of treatment, a finding that has important implications for long-term outcomes. Many newer second-generation antipsychotics have not been studied in FEP. The self-reported Drug Attitude Inventory may help identify patients at heightened risk for medication discontinuation. In addition to vigilant monitoring for and adequate treatment of psychopathology and medication side effects, Relapse Prevention Therapy and the use of long-acting injectable agents may be effective interventions decrease discontinuation rates in FEP. There is currently no consensus on how long a patient should remain on an antipsychotic medication following remission of FEP. Studies are needed to identify predictors of which patients in remission from FEP are less likely to relapse when medication is discontinued. Taken together, our findings presented here underscore the importance of addressing medication discontinuation both as a means of preventing long-term morbidity and enhancing remission and functional recovery in FEP.
Abstract
“All-causes discontinuation” refers to discontinuation of treatment for any reason, and medication adherence is an important component of this measure. Similar to our previous results, we found that almost 30% of patients with first-episode psychosis (FEP) discontinue medication in the first 9 months of treatment, a finding that has important implications for long-term outcomes. Many newer second-generation antipsychotics have not been studied in FEP. The self-reported Drug Attitude Inventory may help identify patients at heightened risk for medication discontinuation. In addition to vigilant monitoring for and adequate treatment of psychopathology and medication side effects, Relapse Prevention Therapy and the use of long-acting injectable agents may be effective interventions decrease discontinuation rates in FEP. There is currently no consensus on how long a patient should remain on an antipsychotic medication following remission of FEP. Studies are needed to identify predictors of which patients in remission from FEP are less likely to relapse when medication is discontinued. Taken together, our findings presented here underscore the importance of addressing medication discontinuation both as a means of preventing long-term morbidity and enhancing remission and functional recovery in FEP.
참고문헌 (31)
- Green AI, "Olanzapine and haloperidol in first episode psychosis: two-year data", Schizophr Res, 86, pp.234~243 (2006)
- McEvoy JP, "Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison", Am J Psychiatry, 164, pp.1050~1060 (2007)
- Kahn RS, "Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial", Lancet, 371, pp.1085~1097 (2008)
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
- Miller BJ, "review of second-generation antipsychotic discontinuation in first-episode psychosis", J Psychiatr Pract, 14, pp.289~300 (2008)
- Buchanan RW, "The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements", Schizophr Bull, 36, pp.71~93 (2010)
- Moore TA, "The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update", J Clin Psychiatry, 68, pp.1751~1762 (2007)
- Lieberman JA, "Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine", Neuropsychopharmacology, 28, pp.995~1003 (2003)
- Schooler N, "Risperidone and haloperidol in firstepisode psychosis: a long-term randomized trial", Am J Psychiatry, 162, pp.947~953 (2005)
- Andersen R, "Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve firstepisode schizophrenia", Psychiatry Res, 187, pp.49~54 (2011)
- Berger GE, "Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg", day vs. 400 mg, J Clin Psychiatry, pp.2008, 69[DOI]
- Emsley R, "Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection", Int Clin Psychopharmacol, 23, pp.325~331 (2008)
- Möller HJ, "Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia", Int J Neuropsychopharmacol, 11, pp.985~997 (2008)
- Takahashi H, "Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial", Clin Neuropharmacol, 32, pp.149~150 (2009)
- Cuesta MJ, "Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis", Br J Psychiatry, 194, pp.439~445 (2009)
- Gafoor R, "Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia", J Clin Psychopharmacol, 30, pp.600~606 (2010)
- Kim B, "Effectiveness of risperidone long-acting injection in firstepisode schizophrenia: in naturalistic setting", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1231~1235 (2008)
- Weiden PJ, "A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome", J Clin Psychiatry, 70, pp.1397~1406 (2009)
- Gaebel W, "Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)", Eur Neuropsychopharmacol, 20, pp.310~316 (2010)
- Malla A, "Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study", Psychol Med, 36, pp.649~658 (2006)
- Perkins DO, "Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible- dose, multicenter study", J Clin Psychiatry, 69, pp.106~113 (2008)
- Robinson D, "Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder", Arch Gen Psychiatry, 56, pp.241~247 (1999)
- Rabiner CJ, "Outcome study of first-episode psychosis. I: Relapse rates after 1 year", Am J Psychiatry, 143, pp.1155~1158 (1986)
- Gitlin M, "Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia", Am J Psychiatry, 158, pp.1835~1842 (2001)
- Lieberman JA, "The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches", Biol Psychiatry, 50, pp.884~897 (2001)
- Robinson DG, "Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder", Updated Am J Psychiatry, 156, pp.544~549 (1999)
- Bachmann S, "One-year outcome and its prediction in first-episode schizophrenia-a naturalistic study", Psychopathology, 41, pp.115~123 (2008)
- Gleeson JF, "A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis", Schizophr Res, 119, pp.79~88 (2010)
- Lehman AF, "guideline for the treatment of patients with schizophrenia, second edition", Am J Psychiatry, 161(2 Suppl), pp.1~56 (2004)
- Wang CY, "Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial", Am J Psychiatry, 167, pp.676~685 (2010)
- Wunderink L, "Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome", J Clin Psychiatry, 68, pp.654~661 (2007)